TickerFactsScreenerDevelopers

Coherus Oncology, Inc. (CHRS) — Cash & Equivalents

Annual figures by fiscal year, from SEC filings.

2011: $7.68M2012: $14.55M2013: $39.55M2014: $150.39M2015: $158.23M2016: $124.95M2017: $126.91M2018: $72.36M2019: $177.67M2020: $541.16M2021: $417.19M2022: $63.55M2023: $102.89M2024: $125.99M2025: $88.88M$88.88M
2011Cash & Equivalents (USD)2025
Fiscal YearCash & EquivalentsChange YoY
2025$88.88M-29.5%
2024$125.99M+22.4%
2023$102.89M+61.9%
2022$63.55M-84.8%
2021$417.19M-22.9%
2020$541.16M+204.6%
2019$177.67M+145.5%
2018$72.36M-43.0%
2017$126.91M+1.6%
2016$124.95M-21.0%
2015$158.23M+5.2%
2014$150.39M+280.2%
2013$39.55M+171.9%
2012$14.55M+89.3%
2011$7.68M—